Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission

• Autor(a) principal: Oliveira-Maia, Albino J.
• Data de Publicação: 2024
• Outros Autores: Rive, Benoît, Godinov, Yordan, Mulhern-Haughey, Siobhán
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10362/174433
• topic: esketamine nasal spray; functional remission; functioning; indirect treatment comparison; patient-reported outcome; Sheehan Disability Scale; treatment resistant depression; Psychiatry and Mental health; SDG 3 - Good Health and Well-being

Funding Information: AJO-M: received grants from Compass Pathways, Ltd., Janssen and Schuhfried GmBH; investigator driven research funded by Funda\u00E7\u00E3o para Ci\u00EAncia e Tecnologia (PTDC/SAU-NUT/3507/2021; PTDC/MED-NEU/1552/2021; PTDC/MED NEU/31331/2017), Funda\u00E7\u00E3o para Ci\u00EAncia e Tecnologia and FEDER (PTDC/MED-NEU/30845/2017_LISBOA-01-0145-FEDER-030845; PTDC/MEC-PSQ/30302/2017_LISBOA-01-0145-FEDER-30302), the European Research Council (ERC-2020-STG-Grant 950357), the European Union Horizon programmes H2020 SC1 2017 CNECT 2 777167 BOUNCE; (H2020 SC1 DTH 2019 875358 FAITH; HORIZON-HLTH-2023-DISEASE-03-101137378-PsyPal) and the European Joint Programme in Rare Diseases (Joint Translational Call 2019) through Funda\u00E7\u00E3o para Ci\u00EAncia e Tecnologia (EJPRD/0001/2020); received payment, honoraria or support for attending meetings from MSD, Neurolite AG Angelini, Janssen and the European Monitoring Centre for Drugs and Drug Addiction; Vice-President of the Portuguese Society for Psychiatry and Mental Health; Head of the Psychiatry Working Group for the National Board of Medical Examination (GPNA) at the Portuguese Medical Association and Portuguese Ministry of Health. BR, YG, and SM-H: Employees of Janssen; hold Johnson & Johnson company stocks/stock options. Funding Information: The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors declare that this study received funding from Janssen EMEA. This article was based on the original studies NCT02497287 and 54135419DEP4001, both sponsored by Janssen EMEA. Support for third-party writing assistance for this article, provided by Laura Mawdsley, MSc, Costello Medical, Cambridge, UK, was funded by Janssen EMEA in accordance with Good Publication Practice (GPP 2022) guidelines. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. Funding Information: The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors declare that this study received funding from Janssen EMEA. This article was based on the original studies NCT02497287 and 54135419DEP4001, both sponsored by Janssen EMEA. Support for third-party writing assistance for this article, provided by Laura Mawdsley, MSc, Costello Medical, Cambridge, UK, was funded by Janssen EMEA in accordance with Good Publication Practice (GPP 2022) guidelines. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. Acknowledgments Publisher Copyright: Copyright © 2024 Oliveira-Maia, Rive, Godinov and Mulhern-Haughey.